Directional diffusion in relapsing-remitting multiple sclerosis: A possible in vivo signature of Wallerian degeneration

被引:60
|
作者
Henry, RG
Oh, JM
Nelson, SJ
Pelletier, D
机构
[1] Univ Calif San Francisco, Dept Radiol, Magnet Resonance Sci Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Neurol, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA
关键词
diffusion tensor imaging; normal-appearing white matter; multiple sclerosis; fiber tracts; Wallerian degeneration;
D O I
10.1002/jmri.10379
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To examine the role of directional dependence of the apparent diffusion coefficients in the evaluation of normal-appearing brain regions of patients with relapsing-remitting multiple sclerosis. Materials and Methods: The role of diffusion tensor eigenvalues was investigated in the normal-appearing brain regions for 18 patients with relapsing-remitting multiple sclerosis and 15 age-matched normal controls. Results: The isotropic apparent diffusion was increased in all regions. However, reduced anisotropy was significant only in regions with high anisotropy, including the corpus callosum and the internal capsule, and was due to increased diffusion tensor eigenvalues corresponding to diffusion transverse to the fibers without significant increase along the fibers. This characteristic pattern of changes in diffusion tensor eigenvalues has been observed previously in cases of Wallerian degeneration. Low-anisotropy regions corresponded to gray matter and gray/white interface regions. Since fiber tract orientations are not determined for regions of low anisotropy, this characteristic pattern of diffusion change is not detectable in these regions. Conclusion: Examination of diffusion tensor eigenvectors may provide insight into the changes observed in diffusion and a signature of Wallerian degeneration in the normal-appearing white matter of relapsing-remitting multiple sclerosis patients.
引用
收藏
页码:420 / 426
页数:7
相关论文
共 50 条
  • [41] Current and future treatments for relapsing-remitting multiple sclerosis
    Birnbaum, Gary
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2010, 13 (02) : 214 - 225
  • [42] CONTEMPORARY TREATMENT OPTIONS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Salhofer-Polanyi, S.
    Leutmezer, F.
    DRUGS OF TODAY, 2014, 50 (05) : 365 - 383
  • [43] Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis
    Nocentini, U
    Pasqualetti, P
    Bonavita, S
    Buccafusca, M
    De Caro, MF
    Farina, D
    Girlanda, P
    Le Pira, F
    Lugaresi, A
    Quattrone, A
    Reggio, A
    Salemi, G
    Savettieri, G
    Tedeschi, G
    Trojano, M
    Valentino, P
    Caltagirone, C
    MULTIPLE SCLEROSIS, 2006, 12 (01): : 77 - 87
  • [44] Peripheral oxidative stress in relapsing-remitting multiple sclerosis
    Tasset, Inmaculada
    Aguelera, Eduardo
    Sanchez-Lopez, Fernando
    Feijoo, Montserrat
    Giraldo, Ana I.
    Cruz, Antonio H.
    Gascon, Felix
    Tunez, Isaac
    CLINICAL BIOCHEMISTRY, 2012, 45 (06) : 440 - 444
  • [45] An investigation of auditory processing in relapsing-remitting multiple sclerosis
    Bissonnette, Jenna N. N.
    Pimer, Laura
    Francis, Ashley M. M.
    Hull, Krista M.
    Leckey, Jennifer
    MacGillivray, Megan
    Berrigan, Lindsay I. I.
    Fisher, Derek J. J.
    EXPERIMENTAL BRAIN RESEARCH, 2023, 241 (05) : 1319 - 1327
  • [46] Cognitive deficits in early relapsing-remitting multiple sclerosis
    Tinnefeld, M.
    Wilhelm, H.
    Daum, I.
    Faustmann, P. M.
    Haase, C. G.
    AKTUELLE NEUROLOGIE, 2008, 35 (01) : 2 - 7
  • [47] Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis
    Young, Carolyn A.
    Rog, David J.
    Sharrack, Basil
    Tanasescu, Radu
    Kalra, Seema
    Harrower, Timothy
    Tennant, Alan
    Mills, Roger J.
    NEUROLOGICAL SCIENCES, 2024, 45 (05) : 2181 - 2189
  • [48] Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis
    Papadopoulou, Athina
    Kappos, Ludwig
    Sprenger, Till
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 749 - 759
  • [49] Immunologic therapy for relapsing-remitting multiple sclerosis.
    MacLean H.J.
    Freedman M.S.
    Current Neurology and Neuroscience Reports, 2001, 1 (3) : 277 - 285
  • [50] Prodrome in relapsing-remitting and primary progressive multiple sclerosis
    Wijnands, J. M. A.
    Zhu, F.
    Kingwell, E.
    Zhao, Y.
    Evans, C.
    Fisk, J. D.
    Marrie, R. A.
    Tremlett, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (07) : 1032 - 1036